Allopurinol in renal ischemia. 2014

Beatriz Prieto-Moure, and Anna Carabén-Redaño, and Alicia Aliena-Valero, and Dolores Cejalvo, and Alexander H Toledo, and Miguel Flores-Bellver, and Natalia Martínez-Gil, and Luis H Toledo-Pereyra, and José Miguel Lloris Carsí
1Experimental Surgery, Universidad Católica de Valencia, Valencia, Spain.

Allopurinol is a xanthine oxidase inhibitor and antioxidant free radical scavenger which facilitates the protection of ischemic organs in part via this mechanism of action. The accumulation of free radicals during ischemia and reperfusion is in great manner overcome by inhibitors of xanthine oxidase and by the development of endogenous antioxidants. The ischemic lesion generates a well-established inflammatory response with the subsequent production of inflammatory molecules characteristically present at the first stages of the injury. Inflammatory cytokines, chemokines, adhesion molecules, and other cellular and molecular compounds are consequently produced as the lesion sets in. Under these conditions, allopurinol diminishes the effect of inflammatory mediators during the ischemic inflammatory response. This study reviews the literature associated with allopurinol and renal ischemia making special emphasis on the best dose and time of administration of allopurinol regarding its protective effect. It also defines the most accepted mechanism of protection on ischemichally damaged kidneys.

UI MeSH Term Description Entries
D007107 Immune System The body's defense mechanism against foreign organisms or substances and deviant native cells. It includes the humoral immune response and the cell-mediated response and consists of a complex of interrelated cellular, molecular, and genetic components. Immune Systems,System, Immune,Systems, Immune
D007511 Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION. Ischemias
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000493 Allopurinol A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms. Allohexal,Allohexan,Alloprin,Allopurin,Allorin,Allpargin,Allural,Apulonga,Apurin,Atisuril,Bleminol,Caplenal,Capurate,Cellidrin,Embarin,Foligan,Hamarin,Jenapurinol,Lopurin,Lysuron,Milurit,Milurite,Novopurol,Pan Quimica,Progout,Pureduct,Purinol,Remid,Rimapurinol,Roucol,Suspendol,Tipuric,Uribenz,Uridocid,Uripurinol,Urosin,Urtias,Xanthomax,Xanturic,Zygout,Zyloprim,Zyloric
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D014969 Xanthine Oxidase An iron-molybdenum flavoprotein containing FLAVIN-ADENINE DINUCLEOTIDE that oxidizes hypoxanthine, some other purines and pterins, and aldehydes. Deficiency of the enzyme, an autosomal recessive trait, causes xanthinuria. Hypoxanthine Oxidase,Hypoxanthine Dehydrogenase,Hypoxanthine-Xanthine Oxidase,Purine-Xanthine Oxidase,Dehydrogenase, Hypoxanthine,Hypoxanthine Xanthine Oxidase,Oxidase, Hypoxanthine,Oxidase, Hypoxanthine-Xanthine,Oxidase, Purine-Xanthine,Oxidase, Xanthine,Purine Xanthine Oxidase

Related Publications

Beatriz Prieto-Moure, and Anna Carabén-Redaño, and Alicia Aliena-Valero, and Dolores Cejalvo, and Alexander H Toledo, and Miguel Flores-Bellver, and Natalia Martínez-Gil, and Luis H Toledo-Pereyra, and José Miguel Lloris Carsí
May 1972, Surgery,
Beatriz Prieto-Moure, and Anna Carabén-Redaño, and Alicia Aliena-Valero, and Dolores Cejalvo, and Alexander H Toledo, and Miguel Flores-Bellver, and Natalia Martínez-Gil, and Luis H Toledo-Pereyra, and José Miguel Lloris Carsí
June 1976, American journal of surgery,
Beatriz Prieto-Moure, and Anna Carabén-Redaño, and Alicia Aliena-Valero, and Dolores Cejalvo, and Alexander H Toledo, and Miguel Flores-Bellver, and Natalia Martínez-Gil, and Luis H Toledo-Pereyra, and José Miguel Lloris Carsí
March 1995, Masui. The Japanese journal of anesthesiology,
Beatriz Prieto-Moure, and Anna Carabén-Redaño, and Alicia Aliena-Valero, and Dolores Cejalvo, and Alexander H Toledo, and Miguel Flores-Bellver, and Natalia Martínez-Gil, and Luis H Toledo-Pereyra, and José Miguel Lloris Carsí
December 2018, Therapeutic advances in cardiovascular disease,
Beatriz Prieto-Moure, and Anna Carabén-Redaño, and Alicia Aliena-Valero, and Dolores Cejalvo, and Alexander H Toledo, and Miguel Flores-Bellver, and Natalia Martínez-Gil, and Luis H Toledo-Pereyra, and José Miguel Lloris Carsí
October 2000, General pharmacology,
Beatriz Prieto-Moure, and Anna Carabén-Redaño, and Alicia Aliena-Valero, and Dolores Cejalvo, and Alexander H Toledo, and Miguel Flores-Bellver, and Natalia Martínez-Gil, and Luis H Toledo-Pereyra, and José Miguel Lloris Carsí
January 2015, Transplantation proceedings,
Beatriz Prieto-Moure, and Anna Carabén-Redaño, and Alicia Aliena-Valero, and Dolores Cejalvo, and Alexander H Toledo, and Miguel Flores-Bellver, and Natalia Martínez-Gil, and Luis H Toledo-Pereyra, and José Miguel Lloris Carsí
January 1998, European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes,
Beatriz Prieto-Moure, and Anna Carabén-Redaño, and Alicia Aliena-Valero, and Dolores Cejalvo, and Alexander H Toledo, and Miguel Flores-Bellver, and Natalia Martínez-Gil, and Luis H Toledo-Pereyra, and José Miguel Lloris Carsí
January 1995, Journal of investigative surgery : the official journal of the Academy of Surgical Research,
Beatriz Prieto-Moure, and Anna Carabén-Redaño, and Alicia Aliena-Valero, and Dolores Cejalvo, and Alexander H Toledo, and Miguel Flores-Bellver, and Natalia Martínez-Gil, and Luis H Toledo-Pereyra, and José Miguel Lloris Carsí
January 2007, Clinical hemorheology and microcirculation,
Beatriz Prieto-Moure, and Anna Carabén-Redaño, and Alicia Aliena-Valero, and Dolores Cejalvo, and Alexander H Toledo, and Miguel Flores-Bellver, and Natalia Martínez-Gil, and Luis H Toledo-Pereyra, and José Miguel Lloris Carsí
December 1989, Helvetica chirurgica acta,
Copied contents to your clipboard!